Clinical

Dataset Information

0

A randomized, controlled, multicenter, phase I/II study of cetuximab plus irinotecan investigating the pharmacodynamics, genomics and -genetics as well as the safety and efficacy of a dose escalation schedule of cetuximab compared with the standard fixed dosing regimen in patients with irinotecan-resistant EGFR expressing metastatic colorectal cancer.


ABSTRACT: Primary objectives: To compare in skin biopsies the effects of an cetuximab dose escalation regimen on EGFR and downstream signaling pathway markers with those of the standard cetuximab regimen Primary endpoints: Expression of EGFR and markers for the downstream signalling pathways in normal skin expressed by means of percentage of stained cells and staining intensity. IHC staining will allow a semi quantitative analysis of protein markers of the EGFR related signalling pathway.

DISEASE(S): Metastatic Colorectal Cancer Refractory To Irinotecan Treatment

PROVIDER: 2515542 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2012-05-22 | E-GEOD-32975 | biostudies-arrayexpress
2012-07-14 | GSE23428 | GEO
2012-05-23 | GSE32975 | GEO
| PRJNA691238 | ENA
2012-07-13 | E-GEOD-23428 | biostudies-arrayexpress
2020-05-06 | GSE108277 | GEO
| PRJNA691245 | ENA
| PRJNA691246 | ENA
2024-07-31 | GSE273572 | GEO
2024-07-31 | GSE273571 | GEO